Obesity, frail obesity, and outcomes after durable left ventricular assist device implantation: a pooled analysis of the MOMENTUM 3 trials

Clicks: 5
ID: 338662
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #375 of 380 articles by views in european heart journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 380 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Obesity in patients supported by left ventricular assist devices (LVADs) is linked to excess mortality and haemocompatibility-related events. Whether this association persists with the fully magnetically levitated HeartMate 3 (HM3) pump is unknown. This analysis tested outcomes with obesity and the additive influence of co-existing frailty (‘frail obesity’) in the contemporary era. Methods The study pooled 2200 HM3 recipients from the MOMENTUM 3 pivotal randomized trial (n = 515) and Continued Access Protocol (n = 1685). Obesity was defined as body mass index (BMI) ≥30 kg/m2 and frailty by a 40-item Rockwood cumulative-deficit frailty index (FI), with clinically relevant frailty defined as FI ≥0.325 (moderate–severe frailty); BMI was excluded from the FI to avoid mathematical coupling. The primary endpoint was survival to transplant, recovery, or 24 months of support free of disabling stroke (modified Rankin score >3) or pump replacement reoperation. Results Obese patients (n = 887, 40.3%) were younger, less often with ischaemic aetiology, and more frequently women, but more often had diabetes and hypertension, than non-obese patients. Unadjusted 2-year outcomes were similar between groups (freedom from the primary endpoint: 75.1% vs 77.1%, log-rank P = .34; survival: 79.9% vs 81.2%, P = .57). After covariate adjustment, obesity was independently associated with a higher risk of the primary endpoint (hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.07–1.58) and all-cause mortality (HR 1.35, 95% CI 1.10–1.67), as well as heart failure hospitalization, infection, and arrhythmia, but not stroke, bleeding, or early right heart failure. Frailty affected 67.3% of obese recipients (571/849) and was associated with a higher adjusted risk of the primary endpoint (HR 1.51, 95% CI 1.09–2.10), overall mortality and non-haemocompatibilty-related morbidity endpoints. The obesity-by-frailty interaction was not significant for either the primary endpoint (P = .436) or mortality (P = .215), indicating additive rather than synergistic risk; frail–obese patients nonetheless carried the highest absolute risk of any subgroup. Frailty improved by at least one severity class by 6 months in 75.9% of frail–obese patients, and improvement was associated with better survival (adjusted HR 0.14, 95% CI 0.07–0.26). Conclusions In the HM3 era, obese and non-obese recipients had similar unadjusted 2-year outcomes; however, after adjustment for baseline case-mix, obesity was independently associated with a higher risk of both the primary endpoint and all-cause mortality, together with heart failure hospitalization, infection, and arrhythmia. Frailty was independently associated with adverse outcomes across nearly all endpoints and was highly prevalent among obese recipients; the combination of obesity and frailty was additive but not synergistic, with frail–obese patients carrying the highest absolute risk. Frailty, however, proved substantially reversible after LVAD support, and its improvement was associated with markedly better survival. Obesity and frailty should therefore be assessed together, rather than through BMI thresholds alone, with recognition that frailty status is dynamic after implantation and that improvement in frailty is associated with markedly better survival.
Reference Key
openalex_W7225246138 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Milica Vukićević, Ameesh M. Isath, Joseph C. Cleveland, Daniel J. Goldstein, Nir Y. Uriel, Svetozar M. Putnik, Carlo Gazzola, Feiyi Jia, Mandeep R. Mehra
Are you one of these authors? Claim your profile
Journal european heart journal
Year 2026
DOI
10.1093/eurheartj/ehag849
URL
https://doi.org/10.1093/eurheartj/ehag849
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.